CSL makes $1.7B bet on first-in-class hopeful

CSL has has entered into an agreement with Alentis Therapeutics worth up to AU$1.7B (US$1.2B) to co-develop and co-promote lixudebart, a potential first-in-class treatment for people with rare kidney and liver disease.

To see the whole article please log in.

Christine Spiteri

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here